Special section on drug metabolism and the microbiome - Commentary drug metabolism by the host and gut microbiota: A partnership or rivalry?

Drug Metabolism and Disposition

Volumn 43, Issue 10, 2015, Pages 1499-1504

  Swanson, Hollie I ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; AMIODARONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; ARSENIC; BENZODIAZEPINE; BILE ACID; BILR 355; CHLORAMPHENICOL; CURCUMIN; CYTOCHROME P450 3A; DIGOXIN; FLAVONOID; HYDRAZINE; IRINOTECAN; MICROBIAL ENZYME; NITROBENZODIAZEPINE; NITROREDUCTASE; PLANT MEDICINAL PRODUCT; POLYCYCLIC AROMATIC HYDROCARBON; PROTON PUMP INHIBITOR; SIMVASTATIN; SULFALAZINE; TACROLIMUS; TRETAZICAR; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; DRUG;

ARTICLE; BACTERIAL METABOLISM; BILE ACID METABOLISM; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG METABOLISM; ENTERITIS; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; HOST; HOST CELL; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; NONHUMAN; POPULATION ABUNDANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; DRUG EFFECTS; HOMEOSTASIS; METABOLISM; MICROFLORA; PHYSIOLOGY;

ANIMALS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMANS; MICROBIOTA; PHARMACEUTICAL PREPARATIONS; XENOBIOTICS;

EID: 84946228284     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.065714     Document Type: Article

References (67)

1. Aura AM, Mattila I, Hyötyläinen T, Gopalacharyulu P, Bounsaythip C, Oresic M, and Oksman-Caldentey KM (2011) Drug metabolome of the simvastatin formed by human intestinal microbiota in vitro. Mol Biosyst 7:437-446.
2. Ball A and Truskewycz A (2013) Polyaromatic hydrocarbon exposure: an ecological impact ambiguity. Environ Sci Pollut Res Int 20:4311-4326.
3. Basit AW and Lacey LF (2001) Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm 227:157-165.
4. Bates J and Diehl L (2014) Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity? J Pathol 232:112-120.
5. Björkholm B., Bok CM, Lundin A, Rafter J., Hibberd ML, and Pettersson S (2009) Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS One 4:e6958.
6. Carmody RN and Turnbaugh PJ (2014) Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest 124:4173-4181.
7. Cheng Y, Jin UH, Allred C.D., Jayraman A., Chapkin RS, and Safe S (2015) Aryl hydrocarbon receptor activity of tryptophan metabolites in young adult mouse colonocytes. Drug Metab Dispos DOI:115.063677 [published ahead of print].
8. Choudhary G and Hansen H (1998) Human health perspective on environmental exposure to hydrazines: a review. Chemosphere 37:801-843.
9. Clarke G, Stilling RM, Kennedy P.J., Stanton C., Cryan JF, and Dinan TG (2014) Minireview. Gut microbiota: the neglected endocrine organ. Mol Endocrinol 28:1221-1238.
10. Claus SP, Ellero SL, Berger B, Krause L., Bruttin A, Molina J, Paris A., Want EJ, de Waziers I, and Cloarec O, et al. (2011) Colonization-induced host-gut microbial metabolic interaction. MBio 2:e00271-e10.
11. Conlon MA and Bird AR (2015) The impact of diet and lifestyle on gut microbiota and human health. Nutrients 7:17-44.
12. Danese S (2011) Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 300:G716-G722.
13. Del Rio D., Rodriguez-Mateos A, Spencer J.P., Tognolini M., Borges G, and Crozier A (2013) Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal 18:1818-1892.
14. Dogra S, Sakwinska O, Soh SE, Ngom-Bru C, Brück WM, Berger B, Brüssow H, Lee YS, Yap F, and Chong YS, et al.; GUSTO Study Group (2015) Dynamics of infant gut microbiota are influenced by delivery mode and gestational duration and are associated with subsequent adiposity. MBio 6:e02419-e14.
15. Franzosa EA, Huang K, Meadow J.F., Gevers D., Lemon KP, Bohannan BJ, and Huttenhower C (2015) Identifying personal microbiomes using metagenomic codes. Proc Natl Acad Sci USA 112:E2930-E2938.
16. Fu J, Wang Z, Huang L., Zheng S, Wang D, Chen S., Zhang H, and Yang S (2014) Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res 28:1275-1283.
17. Gadaleta RM, Cariello M, Sabbà C, and Moschetta A (2015) Tissue-specific actions of FXR in metabolism and cancer. Biochim Biophys Acta 1851:30-39.
18. Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, and Kobayashi M (2011) Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci USA 108:6615-6620.
19. Hubbard TD, Murray IA, and Perdew GH (2015) Indole and tryptophan metabolism: endogenous and dietary routes to Ah receptor activation. Drug Metab Dispos.
20. Integrative HMPRNC; Integrative HMP (iHMP) Research Network Consortium (2014) The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16:276-289.
21. Johansson ME, Larsson JM, and Hansson GC (2011) The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA 108 (Suppl 1):4659-4665.
22. Kapetanovic IM, Lyubimov AV, Kabirova E.V., Kabirov KK, Rasay L, Swezey R, Green C., and Kopelovich L (2012) Effects of bacterial and presystemic nitroreductase metabolism of 2-chloro-5-nitro-N-phenylbenzamide on its mutagenicity and bioavailability. Chem Biol Interact 197:16-22.
23. Kim DH (2015) Gut microbiota-mediated drug-antibiotic interactions. Drug Metab Dispos DOI: dmd.115.063867 [published ahead of print].
24. Klaassen CD and Cui JY (2015) Mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos.
25. Köhle C and Bock KW (2009) Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 77:689-699.
26. Kumar P, Rajasekaran K, Palmer J.M., Thakar MS, and Malarkannan S (2013) IL-22: an evolutionary missing-link authenticating the role of the immune system in tissue regeneration. J Cancer 4:57-65.
27. Kwok CS, Arthur AK, Anibueze C.I., Singh S., Cavallazzi R, and Loke YK (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107:1011-1019.
28. Laparra JM and Sanz Y (2010) Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 61(3):219-225.
29. Lee JR, Muthukumar T, Dadhania D., Taur Y, Jenq RR, Toussaint N.C., Ling L., Pamer E, and Suthanthiran M (2015) Gut microbiota and tacrolimus dosing in kidney transplantation. PLoS One 10:e0122399.
30. Li C, Li Q, Mei Q., and Lu T (2015) Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci 126:57-68.
31. Li H and Jia W (2013) Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther 94:574-581.
32. Li Y, Xu J, Lai W.G., Whitcher-Johnstone A, and Tweedie DJ (2012) Metabolic switching of BILR 355 in the presence of ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase. Drug Metab Dispos 40:1130-1137.
33. Lin Wu S.W., Wu CA, Peng F.C., and Wang AH (2012) Structure-based development of bacterial nitroreductase against nitrobenzodiazepine-induced hypnosis. Biochem Pharmacol 83: 1690-1699.
34. Lu K, Abo RP, Schlieper K.A., Graffam ME, Levine S, Wishnok JS, Swenberg J.A., Tannenbaum SR, and Fox JG (2014) Arsenic exposure perturbs the gut microbiome and its metabolic profile in mice: an integrated metagenomics and metabolomics analysis. Environ Health Perspect 122:284-291.
35. Maranduba CM, De Castro SB, de Souza GT, Rossato C, da Guia FC, Valente MA, Rettore JV, Maranduba CP, de Souza CM, and do Carmo AM, et al. (2015) Intestinal microbiota as modulators of the immune system and neuroimmune system: impact on the host health and homeostasis. J Immunol Res 2015:931574.
36. Matuskova Z, Anzenbacherova E, Vecera R., Tlaskalova-Hogenova H, Kolar M, and Anzenbacher P (2014) Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. PLoS One 9:e87150.
37. Maurice CF, Haiser HJ, and Turnbaugh PJ (2013) Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152:39-50.
38. McCabe M, Sane RS, Keith-Luzzi M, Xu J., King I, Whitcher-Johnstone A, Johnstone N, Tweedie D.J., and Li Y (2015) Defining the role of gut bacteria in the metabolism of deleobuvir: in vitro and in vivo studies. Drug Metab Dispos DOI: dmd.115.064477 [published ahead of print].
39. McDermott AJ and Huffnagle GB (2014) The microbiome and regulation of mucosal immunity. Immunology 142:24-31.
40. Mercier C, Chalansonnet V, Orenga S., and Gilbert C (2013) Characteristics of major Escherichia coli reductases involved in aerobic nitro and azo reduction. J Appl Microbiol 115:1012-1022.
41. Murray IA, Patterson AD, and Perdew GH (2014) Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer 14:801-814.
42. Prosser GA, Copp JN, Syddall S.P., Williams EM, Smaill JB, Wilson WR, Patterson A.V., and Ackerley DF (2010) Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol 79:678-687.
43. Ridaura V and Belkaid Y (2015) Gut microbiota: the link to your second brain. Cell 161:193-194.
44. Roldán M.D., Pérez-Reinado E, Castillo F, and Moreno-Vivián C (2008) Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev 32:474-500.
45. Rosenfeld CS (2015) Microbiome disturbances and autism spectrum disorders. Drug Metab Dispos 43:1557-1571.
46. Ruan JQ, Li S, Li Y.P., Wu WJ, Lee MS, and Yan R (2015) The presystemic interplay between gut microbiota and orally administered calycosin-7-O-β-D-glucoside. Drug Metab Dispos dmd.115.065094 [published ahead of print].
47. Rubin DC, SS, Alava P, Zekker I, Du Laing G, and Van de Wiele T (2014) Arsenic thiolation and the role of sulfate-reducing bacteria from the human intestinal tract. Environ Health Perspect 122:817-822.
48. Sayin SI, Wahlström A, Felin J., Jäntti S, Marschall H.U., Bamberg K., Angelin B, Hyötyläinen T, Orešič M, and Bäckhed F (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17: 225-235.
49. Scott KP, Antoine JM, and Midtvedt T, and Van Hemert S (2015) Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis 26:25877.
50. Selwyn FP, Csanaky IL, Zhang Y, and Klaassen CD (2015a) Importance of large intestine in regulating bile acids and GLP-1 in germ-free mice. Drug Metab Dispos.
51. Selwyn FP, Cui JY, and Klaassen CD (2015b) RNA-Seq quantification of hepatic drug processing genes in grem-free mice. Drug Metab Dispos DOI: dmd.115.063545 [published ahead of print].
52. Shen W, Gaskins HR, and McIntosh MK (2014) Influence of dietary fat on intestinal microbes, inflammation, barrier function and metabolic outcomes. J Nutr Biochem 25:270-280.
53. Sousa T, Paterson R, Moore V., Carlsson A, Abrahamsson B, and Basit AW (2008) The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 363:1-25.
54. Sowada J, Schmalenberger A, Ebner I., Luch A, and Tralau T (2014) Degradation of benzo[a] pyrene by bacterial isolates from human skin. FEMS Microbiol Ecol 88:129-139.
55. Swann J, Wang Y, Abecia L., Costabile A, Tuohy K, Gibson G., Roberts D, Sidaway J, Jones H., and Wilson ID, et al. (2009) Gut microbiome modulates the toxicity of hydrazine: a metabonomic study. Mol Biosyst 5:351-355.
56. Swanson HI, Wada T, Xie W., Renga B, Zampella A, Distrutti E., Fiorucci S, Kong B, Thomas A.M., and Guo GL, et al. (2013) Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos 41:1-11.
57. Sweeny DJ, Li W, Clough J., Bhamidipati S, Singh R, Park G., Baluom M, Grossbard E, and Lau DT (2010) Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 38:1166-1176.
58. Toda T, Saito N, Ikarashi N., Ito K, Yamamoto M, Ishige A., Watanabe K, and Sugiyama K (2009) Intestinal flora induces the expression of Cyp3a in the mouse liver. Xenobiotica 39(4): 323-334.
59. Van de Wiele T, Vanhaecke L, Boeckaert C, Peru K, Headley J, Verstraete W, and Siciliano S (2005) Human colon microbiota transform polycyclic aromatic hydrocarbons to estrogenic metabolites. Environ Health Perspect 113:6-10.
60. Wallace BD, Wang H, Lane K.T., Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C., Yeh LA, and Mani S, et al. (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330:831-835.
61. Wu JC, Tsai ML, Lai C.S., Wang YJ, Ho CT, and Pan MH (2014) Chemopreventative effects of tetrahydrocurcumin on human diseases. Food Funct 5:12-17.
62. Yadav V, Gaisford S, Merchant H.A., and Basit AW (2013) Colonic bacterial metabolism of corticosteroids. Int J Pharm 457:268-274.
63. Yatsunenko T, Rey FE, Manary M.J., Trehan I., Dominguez-Bello MG, Contreras M, Magris M., Hidalgo G, Baldassano RN, and Anokhin AP, et al. (2012) Human gut microbiome viewed across age and geography. Nature 486:222-227.
64. Yip LY and Chan ECY (2015) Investigation of host-gut microbiota modulation of therapeutic outcome. Drug Metab Dispos DOI: dmd.115.063750 [published aahead of print].
65. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G., Zecchi R, D'Angelo C, Massi-Benedetti C, and Fallarino F, et al. (2013) Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39:372-385.
66. Zhang YZ and Li YY (2014) Inflammatory bowel disease: pathogenesis. World J Gastroenterol 20:91-99.
67. Zhou J, Ma YH, Zhou Z, Chen Y., Wang Y, and Gao X (2015) Intestinal absorption and metabolism of epimedium flavonoids on osteoporosis rats. Drug Metab Dispos DOI: dmd.115.064386 [published ahead of print].